Objective: This study aimed to measure and compare the effectivity and cost of the two types of ceftriaxone to determine the more cost-effective treatment. Methods:In a cross-sectional analytical study, prescription and administrative financial data were retrospectively collected using the total sampling method. Data of 63 patients, comprising 43 and 20 patients treated with generic and patent ceftriaxone, respectively, were analyzed. The effectiveness of the treatment was measured in terms of the length of hospital stay of the patients. The total cost of the treatment was the total median of the costs of drugs, laboratory examinations, medical device usage, physician service, and hospitalization. Results:The effectiveness of both generic and patent ceftriaxone was 4 days of hospital stay. Cost-effectiveness ratio of generic ceftriaxone was Rp 575,937.25/day and that of patent ceftriaxone was Rp 888,601.75/day. Conclusion:Generic ceftriaxone was more cost-effective than patent ceftriaxone.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.